Forma nets $65M upfront from Boehringer to drug "undruggable" cancer targets

Forma Therapeutics has snagged a potentially lucrative deal in a cancer drug discovery partnership with Boehringer Ingelheim. The deal provides Forma with $65 million in up-front payments and four years' worth of continual R&D funding, and the potential for $750 million in pre-commercial milestones for programmes resulting from the collaboration.